




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Novel Agents</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=a6997643-d7bf-4b8d-b578-d65877161636</link>
        <description>Clinical Topic Feed: Novel Agents</description>
        <language>en</language>

        

                <item>
                    <title>Eagle&#226;€™s Eye View: Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair </title>
<link>/Latest-in-Cardiology/Articles/2026/06/16/16/01/eagles-eye-view-17jun2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men.</description>
                    <pubdate>1781701440000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>SOGALDI-PEF: Baseline Renin Levels Predict BP Treatment Effect</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/08/17/44/SOGALDI-PEF</link>                    <description>Patients with low plasma renin levels had a more pronounced blood pressure (BP) reduction with spironolactone/dapagliflozin vs. dapagliflozin alone, in addition to seeing a more favorable impact on cardiovascular structure and function, while aldosterone levels exhibited no predictive value in treatment response...</description>
                    <pubdate>1781118900000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>New Research Shows Benefits of Evolocumab, Laroprovstat</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/03/20/12/New-Research</link>                    <description>Three new studies published in Circulation highlight advances in lipid-lowering therapy, with early-stage data supporting a first-in-class oral PCSK9 inhibitor and two separate analyses showing that evolocumab reduces major cardiovascular events across a range of high-risk patients, including those with elevated Lp(a) and those with prior PCI but no history of MI.</description>
                    <pubdate>1780519500000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Maintaining Weight Loss With Tirzepatide</title>
<link>/Latest-in-Cardiology/Articles/2026/05/27/15/57/eagles-eye-view-27may2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment.</description>
                    <pubdate>1779898740000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>New Studies Add to Evidence Involving Optimal Treatment of Patients Post-Ischemic Stroke</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/18/18/10/New-Studies-Add-to-Evidence</link>                    <description>Treatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase.</description>
                    <pubdate>1779219300000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC Spotlight Issue Provides Expert Insight on 2026 Dyslipidemia Guideline</title>
<link>/Latest-in-Cardiology/Articles/2026/05/19/15/49/JACC-Spotlight-Issue-2026-Dyslipidemia-Guideline</link>                    <description>A special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations...</description>
                    <pubdate>1779206040000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | Electronic Alerts For Managing AS, MR; More</title>
<link>/Latest-in-Cardiology/Articles/2026/05/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1777637400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF</title>
<link>/Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap</link>                    <description>The hottest research from various peer-reviewed journals &#226;€“ handpicked weekly by the ACC.</description>
                    <pubdate>1777637340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Journal Wrap | Renal Function Change and Post M-TEER Survival; Pregnancy Biomarkers and CV Risk; More</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/01/Journal-Wrap</link>                    <description>The hottest research from various peer-reviewed journals &#226;€“ handpicked weekly by the ACC.</description>
                    <pubdate>1775045400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>VESALIUS-CV: Evolocumab Reduces CV Risk in Diabetic Patients Without ASCVD</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-345pm-vesaliuscv-acc-2026</link>                    <description>The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in JAMA.</description>
                    <pubdate>1774730760000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>